Showing 3771-3780 of 5773 results for "".
- New Study Highlights Patient Willingness to Adhere to Pre-Op Prephttps://modernod.com/news/new-study-highlights-patient-willingness-to-adhere-to-pre-op-prep/2480874/Bruder Healthcare announced new research that supports cataract surgeons and comanaging optometrists and ophthalmologists as they help patients prepare for surgery. This noninterventional, cross-sectional investigation of 278 US adults age 65 and older sought to identify cataract s
- Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officerhttps://modernod.com/news/visiox-pharma-appoints-ryan-s-bleeks-as-chief-executive-officer/2480872/Visiox Pharma announced the appointment of Ryan S. Bleeks as Chief Executive Officer. "We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's Founding Investor and Executive Chairman. "His
- Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101https://modernod.com/news/qlaris-bio-reports-phase-2-clinical-trial-results-demonstrating-favorable-safety-and-tolerability-profile-and-positive-efficacy-signal-for-qls-101/2480871/Qlaris Bio announced results from QC-201, a first-in-human, phase 2 clinical trial of QLS-101, the company’s investigational therapy for lowering IOP in the treatment of glaucoma. Study findings demonstrated a favorable safety and tolerability profile for QLS-101, including no evi
- United Kingdom First to Grant License for Teva’s Ophthalmology Biosimilar Ongavia (Ranibizumab)https://modernod.com/news/united-kingdom-first-to-grant-license-for-tevas-ophthalmology-biosimilar-ongavia-ranibizumab/2480870/Teva Pharmaceutical announced that the UK Medicines & Healthcare Regulatory Agency (MHRA) has granted a licence for Ongavia, a biosimilar to Lucentis (ranibizumab). The United Kingdom is the first country in Europe to authorize commercialization of Ongavia for
- Prevent Blindness and Aerie Pharmaceuticals Partner to Offer New Glaucoma Research Granthttps://modernod.com/news/prevent-blindness-and-aerie-pharmaceuticals-partner-to-offer-new-glaucoma-research-grant/2480868/Research to Prevent Blindness (RPB) and Aerie Pharmaceuticals are partnering to provide early- to mid-career vision scientists with opportunities to pursue glaucoma research of unusual significance and promise. RPB announced the launch the RPB/David L. Epstein Career Advancem
- 2022 Bressler Prize Awarded to Dr. Sheila Nirenberg for Outstanding Accomplishments in Vision Sciencehttps://modernod.com/news/2022-bressler-prize-awarded-to-dr-sheila-nirenberg-for-outstanding-accomplishments-in-vision-science/2480866/Not-for-profit Lighthouse Guild announced today that Sheila Nirenberg, PhD, has been awarded the 2022 Bressler Prize for her outstanding advances in vision science, including deciphering the retina’s neural code which is the key to restoring meaningful vision in people who are blind fr
- Visionix and Right MFG to Enter a Long-Term Strategic Partnershiphttps://modernod.com/news/visionix-and-right-mfg-to-enter-a-long-term-strategic-partnership/2480863/Visionix, formerly Luneau Technology, and Japan-based Right MFG announced today that they have entered a long-term strategic partnership agreement with the aim of accelerating growth for both companies. Financial terms of the deal were not disclosed.
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to Iluvien Use for IOP Outcomeshttps://modernod.com/news/phase-4-paladin-study-confirms-positive-predictive-value-of-corticosteroid-course-prior-to-iluvien-use-for-iop-outcomes/2480855/Alimera Sciences announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the Iluvien U.S. label to mitigate the risk of uncontrolled IOP elevation. These results were presented at the annual Association for Researc
- Eyevensys Recaps Highlights from Investigator Meeting and Presentations at ARVOhttps://modernod.com/news/eyevensys-recaps-highlights-from-investigator-meeting-and-presentations-at-arvo/2480854/Eyevensys provided highlights from the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference in Denver, Colorado. In addition to its participation in the event, Eyevensys also held a successful meeting with principal investigators involved in its clinical trials